Discovery and mechanism of ustekinumab

Monoclonal antibody (mAb) therapy was first established upon the approval of a mouse antibody for treatment of human acute organ rejection. However, the high incidence of immune response against the mouse mAb restricted therapeutic utility. Development of chimeric, “humanized” and human mAbs broadened therapeutic application to immune-mediated diseases requiring long-term treatment. Indeed, mAb therapeutics targeting soluble cytokines are highly effective in numerous immune-mediated disorders. A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets. Ustekinumab was generated via recombinant human IL-12 immunization of human immunoglobulin (hu-Ig) transgenic mice. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes. Ustekinumab is approved for treatment of moderate-to-severe plaque psoriasis and has demonstrated efficacy in Crohn disease and psoriatic arthritis. The clinical characterization of ustekinumab continues to clarify our understanding of human immune pathologies and may offer a novel therapeutic option for certain immune-mediated diseases.

[1]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[2]  G. Morrone,et al.  Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. , 1997, Gastroenterology.

[3]  Jinquan Luo,et al.  Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. , 2010, Journal of molecular biology.

[4]  M. Kamoun,et al.  IL-12p35-Deficient Mice Are Susceptible to Experimental Autoimmune Encephalomyelitis: Evidence for Redundancy in the IL-12 System in the Induction of Central Nervous System Autoimmune Demyelination1 , 2002, The Journal of Immunology.

[5]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[6]  H. Schild,et al.  Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. , 2010, Immunity.

[7]  K. Garcia,et al.  The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. , 2008, Journal of molecular biology.

[8]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[9]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[10]  H. Yang,et al.  A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Mascelli,et al.  Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives , 2011, Annals of the New York Academy of Sciences.

[12]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[13]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[14]  K. Peris,et al.  The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans , 2011, PloS one.

[15]  M. Hennerici,et al.  Increased release of interleukin-12p40 in MS , 1998, Neurology.

[16]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[17]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[18]  A. Rachitskaya,et al.  Cutting Edge: NKT Cells Constitutively Express IL-23 Receptor and RORγt and Rapidly Produce IL-17 upon Receptor Ligation in an IL-6-Independent Fashion1 , 2008, The Journal of Immunology.

[19]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[20]  S. Travis,et al.  IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.

[21]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[22]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[23]  C. Morita,et al.  Cytokine Requirements for the Differentiation and Expansion of IL-17A– and IL-22–Producing Human Vγ2Vδ2 T Cells , 2010, The Journal of Immunology.

[24]  F. Kerdel,et al.  Short Communication Mediators of Inflammation, 12(5), 309 /313 (October 2003) BACKGROUND: Psoriatic plaques have been shown to , 2022 .

[25]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[26]  Reinhard Guthke,et al.  Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept , 2008, Arthritis research & therapy.

[27]  T. Raju,et al.  The Nobel Chronicles , 2000, The Lancet.

[28]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[29]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[30]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[31]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[32]  A Y Finlay,et al.  The family impact of skin diseases: the Greater Patient concept , 2007, The British journal of dermatology.

[33]  O. Arican,et al.  Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity , 2005, Mediators of inflammation.

[34]  M. Feldmann,et al.  Localization of tumour necrosis factor‐alpha (TNF‐α) and its receptors in normal and psoriatic skin: epidermal cells express the 55‐kD but not the 75‐kD TNF receptor , 1993, Clinical and experimental immunology.

[35]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[36]  E. Berg,et al.  IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. , 1999, Journal of immunology.

[37]  H. Okamura,et al.  IL-12 and IL-18 Are Increased and Stimulate IFN-γ Production in Sarcoid Lungs , 2001, The Journal of Immunology.

[38]  J. Leonard,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 , 1995, The Journal of experimental medicine.

[39]  E. Assier,et al.  Interleukin-23: A key cytokine in inflammatory diseases , 2011, Annals of medicine.

[40]  M. Goldman,et al.  IL‐23 up‐regulates IL‐10 and induces IL‐17 synthesis by polyclonally activated naive T cells in human , 2005, European journal of immunology.

[41]  P. Pasquini,et al.  Prevalence and correlates of suicidal ideation among patients with skin disease. , 2006, Journal of the American Academy of Dermatology.

[42]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[43]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[44]  J. Krueger,et al.  Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research , 2007, The British journal of dermatology.

[45]  N. Lonberg,et al.  High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. , 1996, Nature biotechnology.

[46]  G. Greenberg,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial , 2011 .

[47]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[48]  Steven R Feldman,et al.  Interleukin-12, interleukin-23, and psoriasis: current prospects. , 2007, Journal of the American Academy of Dermatology.

[49]  T. Mosmann,et al.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.

[50]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[51]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[52]  A. Finlay,et al.  Psoriasis has a major secondary impact on the lives of family members and partners , 2007, The British journal of dermatology.

[53]  C. Mackay,et al.  Follicular B helper T cells in antibody responses and autoimmunity , 2005, Nature Reviews Immunology.

[54]  Frank O. Nestle,et al.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis , 2007, Human Genetics.

[55]  Honghui Zhou,et al.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab , 2011, Nature Biotechnology.

[56]  T. Mcclanahan,et al.  Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation , 2003, The Journal of experimental medicine.

[57]  F. Nicoletti,et al.  Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis , 1996, Journal of Neuroimmunology.

[58]  A. Gurney,et al.  Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17* , 2003, The Journal of Biological Chemistry.

[59]  J. Reichert.  Antibodies to watch in 2010 , 2010, mAbs.

[60]  J. T. Dissel,et al.  IL-23 modulates CD56+/CD3− NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12 , 2009 .

[61]  W. Somers,et al.  Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin‐12 , 2000, The EMBO journal.

[62]  M. Leach,et al.  IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. , 1998, Journal of immunology.

[63]  Brennan,et al.  Blockade of IL‐12 during the induction of collagen‐induced arthritis (CIA) markedly attenuates the severity of the arthritis , 1998, Clinical and experimental immunology.

[64]  O. Westphal,et al.  Paul Ehrlich--in search of the magic bullet. , 2004, Microbes and infection.

[65]  Steven J. Schrodi,et al.  A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.

[66]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[67]  L. Chun.  IL-17-producing γδ T cells , 2012 .

[68]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[69]  E. Christophers.  Psoriasis − epidemiology and clinical spectrum , 2001, Clinical and experimental dermatology.

[70]  H. Okamura,et al.  IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. , 2001, Journal of immunology.

[71]  J. Cézard,et al.  Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. , 1998, The American journal of pathology.

[72]  W. Strober,et al.  Cutting Edge: Regulatory T Cells Induce CD4+CD25−Foxp3− T Cells or Are Self-Induced to Become Th17 Cells in the Absence of Exogenous TGF-β , 2007, The Journal of Immunology.

[73]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.